NCBiotech News

Type 2 diabetes patients may soon have an option to inhale insulin through a device from Durham's Aerami Therapeutics that acts faster and lasts longer than Lilly’s injected insulin.

A $1.1 million U.S. Department of Defense grant will support Morrisville-based Novan’s efforts to develop a new defense against cervical cancer.

Hanging on to North Carolina's dominance in agricultural technology requires continued investment and innovation, said panelists at the North Carolina Biotechnology Center’s September AgTech Professional Forum.

Durham’s Mycovia Pharmaceuticals has emerged as the winner over nine finalist life science startups from across the nation vying for recognition in the “Buzz of BIO” Late Stage Leaders competition, part of the BIO Investor Forum taking place in San Francisco in October. 

Applications for the Vicky Amidon Innovation Grant in Lung Cancer Research Award are due Oct. 1.

The NCBiotech Agriculture Sector Development team is partnering with local agriculture organizations to highlight women in agriculture across North Carolina.

Precision BioSciences, a genome-editing company based in Durham, has received authorization from the U.S. Food and Drug Administration to advance its second genome-edited cancer therapy to clinical trials.  

Durham-based Arbiom is challenging the world of animal feed by utilizing wood waste as a source of protein.

Durham’s Mycovia Pharmaceuticals is one of nine startups scrambling for last-minute votes in the “Buzz of BIO” Late Stage Leaders competition, part of the BIO Investor Forum taking place in San Francisco this October.

RFPi, a Greenville medical device company, has landed a groundbreaking $1.49 million NIH grant with ECU as its academic research partner.

The North Carolina Biotechnology Center has launched the inaugural installment of its new podcast series, “Transformation Talks.” The 22-minute program, hosted by Jim Shamp, NCBiotech’s director of public relations, features former Biotech Center president Charles Hamner Jr., D.V.M., and Bill Bullock, senior vice president of economic development and statewide operations.

Accelerated Enrollment Solutions, a business unit of Wilmington’s Pharmaceutical Product Development, has purchased the clinical research site business of clinical trial development company Bioclinica.

Durham contract services organization KBI Biopharma is working with two other companies to develop a novel therapy to treat inflammatory diseases.

North Carolina is taking an increasing leadership role in precision health as we apply new technologies to our deepening understanding of how people’s genetic makeup and other factors impact their wellbeing.

Registration is open for the Sept. 25 and 26 "Invest in Cures & Rare Disease Forum," bringing together potential investors, collaborators and NC therapeutics developers to find new ways to deal with orphan diseases.